New genomic test could spare thousands of breast cancer patients from chemotherapy
NCT ID NCT07379918
First seen Feb 02, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study is looking at a test called EndoPredict that helps doctors decide if women with a certain type of early breast cancer need chemotherapy or just hormone therapy. The test measures the risk of the cancer coming back over 10 years. The goal is to see if using this test in real life can safely allow some patients to skip chemotherapy. About 1,000 women are being followed for 10 years to track their health outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint-Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.